BlueCrest Capital Management Ltd lessened its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 47.5% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 6,975 shares of the company’s stock after selling 6,312 shares during the period. BlueCrest Capital Management Ltd’s holdings in IDEXX Laboratories were worth $1,091,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Wells Fargo & Company MN grew its position in shares of IDEXX Laboratories by 7.8% in the 3rd quarter. Wells Fargo & Company MN now owns 338,968 shares of the company’s stock valued at $52,706,000 after buying an additional 24,510 shares during the last quarter. Macquarie Group Ltd. grew its position in shares of IDEXX Laboratories by 7.0% in the 3rd quarter. Macquarie Group Ltd. now owns 38,000 shares of the company’s stock valued at $5,909,000 after buying an additional 2,500 shares during the last quarter. Atlantic Trust Group LLC bought a new stake in shares of IDEXX Laboratories in the 3rd quarter valued at about $65,381,000. IFM Investors Pty Ltd bought a new stake in shares of IDEXX Laboratories in the 3rd quarter valued at about $337,000. Finally, Swiss National Bank grew its position in shares of IDEXX Laboratories by 1.0% in the 3rd quarter. Swiss National Bank now owns 324,500 shares of the company’s stock valued at $50,457,000 after buying an additional 3,300 shares during the last quarter. Hedge funds and other institutional investors own 87.09% of the company’s stock.
In related news, Director William T. End sold 4,000 shares of the company’s stock in a transaction that occurred on Thursday, February 22nd. The stock was sold at an average price of $184.48, for a total transaction of $737,920.00. Following the transaction, the director now directly owns 41,256 shares of the company’s stock, valued at approximately $7,610,906.88. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CEO Jonathan W. Ayers sold 18,000 shares of the company’s stock in a transaction that occurred on Tuesday, January 9th. The stock was sold at an average price of $165.15, for a total value of $2,972,700.00. Following the transaction, the chief executive officer now directly owns 1,077,112 shares in the company, valued at $177,885,046.80. The disclosure for this sale can be found here. Insiders sold a total of 91,736 shares of company stock worth $16,193,502 over the last three months. 2.77% of the stock is owned by company insiders.
IDEXX Laboratories (NASDAQ:IDXX) last announced its quarterly earnings data on Thursday, February 1st. The company reported $0.77 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.73 by $0.04. The company had revenue of $506.00 million for the quarter, compared to the consensus estimate of $490.51 million. IDEXX Laboratories had a negative return on equity of 432.19% and a net margin of 13.36%. The firm’s revenue was up 14.2% compared to the same quarter last year. During the same period in the previous year, the business earned $0.58 EPS. sell-side analysts predict that IDEXX Laboratories, Inc. will post 4.09 earnings per share for the current fiscal year.
A number of research firms have commented on IDXX. Aegis reiterated a “sell” rating on shares of IDEXX Laboratories in a research report on Friday, December 8th. Canaccord Genuity reiterated a “buy” rating and issued a $210.00 price target on shares of IDEXX Laboratories in a research report on Monday, January 29th. Piper Jaffray Companies began coverage on IDEXX Laboratories in a research note on Tuesday, January 16th. They issued an “overweight” rating and a $200.00 price objective on the stock. BidaskClub raised IDEXX Laboratories from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, March 7th. Finally, Bank of America boosted their price objective on IDEXX Laboratories from $200.00 to $220.00 and gave the company a “buy” rating in a research note on Friday, February 2nd. One research analyst has rated the stock with a sell rating, five have given a buy rating and two have given a strong buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $194.00.
TRADEMARK VIOLATION WARNING: This piece of content was first posted by American Banking News and is owned by of American Banking News. If you are accessing this piece of content on another site, it was illegally copied and reposted in violation of U.S. and international trademark and copyright legislation. The correct version of this piece of content can be accessed at https://www.americanbankingnews.com/2018/03/14/bluecrest-capital-management-ltd-has-1-09-million-holdings-in-idexx-laboratories-inc-idxx.html.
IDEXX Laboratories Company Profile
IDEXX Laboratories, Inc develops, manufactures and distributes products and provides services for the companion animal veterinary, livestock and poultry, dairy and water testing markets. The Company also sells a line of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market.
Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX).
Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.